The use of the CRISPR/Cas9 method to edit HLA-G from these cancer cells has indeed succeeded in reversing the induction mediated by HLA-G in wild-type RCC7 cells, demonstrating the direct implication of HLA-G in the regulation of NCAM1 expression. Here, NCAM1 is linked to cancer.